MIAMI– Carevive Systems (“Carevive”) the leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer, today announced that it has appointed Aaron Galaznik, M.D. as Chief Scientific Officer. In this new role, Dr. Galaznik will lead all scientific and clinical activities associated with Carevive, including its real-world evidence (RWE) and patient reported outcomes (PRO) strategies.
Dr. Galaznik brings more than 15 years of experience in real-world data and analytics to Carevive. He comes to the company from Medidata, where he served as Head of RWE Research Solutions. In this role, Dr. Galaznik architected Medidata’s center of excellence for patient-level longitudinal data, building the team and bridging the gap between clinical trial and real-world data.
“Gathering data regularly and actionably is a critical way to ensure we are optimizing care for patients undergoing treatment for cancer,” said Dr. Galaznik. “Carevive is improving how care for these patients is delivered by leveraging critical real-world data and technology to develop the tools of tomorrow, instead of simply working with the tools we have today. I am thrilled to join the team and look forward to contributing to this important effort.”
Prior to Medidata, Dr. Galaznik served as Senior Director, Global Outcomes Research at Takeda where he developed and executed outcomes evidence generation strategies for oncologic compounds in early clinical development and oversaw implementation of robust PRO strategies as part of their development plans. Before his time at Takeda, Dr. Galaznik served as Senior Director of RWD and Analytics at Pfizer where he drove strategies on acquisition and utilization of longitudinal clinical datasets throughout the enterprise.
“We are excited to welcome Aaron to the Carevive family, someone I have had the pleasure of working with previously,” said Bruno Lempernesse, Chief Executive Officer of Carevive. “Being both a physician by training and a renowned expert in RWE generation strategies uniquely positions him as someone who can help us deliver on our mission of improving outcomes for patients with cancer, both now and in the future.”
